Company Overview
Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical company dedicated to the acquisition, development, and commercialization of prescription products, specifically offering Acetadote for acetaminophen poisoning and Caldolor for pain management. The firm functions within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which defines its operational focus on niche therapeutic areas rather than broad-market medications. The company currently maintains a market capitalization of $45.92M and employs 93 individuals to support its product portfolio. With an annual revenue of $44.52M, the entity operates as a micro-cap entity, indicating a specialized position within the pharmaceutical landscape where scale is derived from specific, high-value products rather than broad sales volume. These valuation and revenue figures suggest the company is a focused player targeting specific medical needs, utilizing a lean operational structure to navigate the competitive specialty drug market.
Financial Health
The company reported a total revenue of $44.52M over the trailing twelve months, while recording a net income of $-2,836,128 and an EBITDA of $1.35M. The significant negative net income relative to the positive revenue stream reveals a cost structure where operating expenses, including research, development, and general administration, exceed gross profits, resulting in an overall loss despite strong sales performance. However, the company generates positive free cash flow of $6.44M, which indicates a degree of financial flexibility allowing for operational investments or debt servicing without immediate reliance on external equity financing. Profitability is further contextualized by a gross margin of 85.0%, reflecting the high value of the specialized pharmaceutical products sold, contrasted by an operating margin of -10.0% and a profit margin of -6.4% that highlight the substantial overhead costs required to sustain the specialty business model. Regarding liquidity and leverage, the company holds $11.44M in cash against $10.18M in debt, supported by a debt-to-equity ratio of 41.48% which suggests a moderately leveraged balance sheet rather than a highly conservative one. Short-term liquidity is maintained with a current ratio of 1.01, indicating that current assets just barely cover current liabilities, a typical state for capital-intensive growth phases in pharmaceutical development. Return metrics such as a return on equity of -12.2% and a return on assets of -2.3% reveal that management effectiveness is currently challenged by the high burn rate associated with the company's growth and product acquisition strategies.
Valuation Assessment
The valuation profile is characterized by a P/E ratio (TTM) of N/A due to the lack of positive net income, while the forward P/E stands at 21.93, implying that the market is pricing in a future trajectory where earnings are expected to become positive or stabilize. The price-to-book ratio is 1.85, indicating that the market values the company at a premium of 85% above its tangible book value, a common occurrence for specialty firms with intangible assets like intellectual property. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 1.03 and an EV/EBITDA of 32.75, suggesting the market assigns a high multiple to revenue and earnings before interest, taxes, depreciation, and amortization relative to the company's current size. The stock has demonstrated significant price volatility over the past year, trading between a 52-week low of $1.85 and a 52-week high of $6.27, with the current price positioned at approximately 64% below the 52-week high. The beta value is recorded as -0.54, a negative figure that indicates the stock's price movements have historically moved inversely to the broader market, presenting a unique risk profile distinct from standard equity instruments.
Growth & Income
Revenue growth is robust at 31.1% year-over-year, whereas earnings growth is N/A due to the company's current net loss status, implying that top-line expansion is outpacing profitability improvements as the firm scales its product offerings. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all earnings to fund operations, acquisitions, and research rather than distributing income to shareholders. The absence of a dividend payout reinforces the strategy of reinvesting capital directly into the growth of the specialty pharmaceutical portfolio and the commercialization of prescription products. Overall, the growth and income profile is defined by aggressive revenue expansion and a total reinvestment strategy that prioritizes market share and product development over immediate income generation for shareholders.